• 復(fù)旦大學(xué)附屬中山醫(yī)院呼吸科( 上海 200032);

支氣管哮喘( 簡稱哮喘) 是氣道的非特異性炎癥性疾病。近年來, 通過規(guī)范化治療, 大部分患者可獲得良好的治療效果, 重癥哮喘的發(fā)生率降低, 需要急診或住院的患者減少[1] 。同時哮喘作為一種不能根治的慢性病, 規(guī)范化治療也意味著需要較長的療程, 隨之可能帶來一定的不良反應(yīng), 但這些不良反應(yīng)又較少受到重視。

引用本文： 陶雪飛,朱蕾. 支氣管哮喘的藥物治療和相關(guān)不良反應(yīng). 中國呼吸與危重監(jiān)護(hù)雜志, 2010, 9(6): 654-656. doi: 復(fù)制

1. Anandan C, Nurmatov U, Van Schayck OC, et al. Is the prevalence of asthma declining? Systematic review of epidemiological studies.Allergy, 2010 , 65: 152-67 .
2. Gibson PG, Powell H, Gibson PG. Initial corticosteroid therapy for asthma. Curr Opin Pulm Med, 2006, 12: 48-53 .
3. Kaiser H. Cortison therapy today. Wien Klin Wochenschr, 2003 ,115: 6 -21 .
4. Sasaki A, Ouchi K, Makata H, et al. The effect of inhaled corticosteroids on Chlamydophila pneumoniae and Mycoplasma pneumoniae infection in children with bronchial asthma. J Infect Chemother, 2009, 15: 99 -103.
5. Mullaoglu S, Turktas H, Kokturk N, et al. Esophageal candidiasis and Candida colonization in asthma patients on inhaled steroids.Allergy Asthma Proc, 2007, 28: 544-549 .
6. Sekine A, Hagiwara E, Ogura T, et al. A case of pulmonary Mycobacterium avium infection presenting multiple nodules with substantial difference in 18F-fluorodeoxyglucose uptake. Nihon Kokyuki Gakkai Zasshi, 2009, 47: 575-580 .
7. Christensson C, Thoren A, Lindberg B, et al. Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects. Drug Saf, 2008 , 31: 965-988.
8. Gluck PA, Gluck JC. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr Med Res Opin,2005, 21: 1075-1084 .
9. Fal AM, Kopec A. Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment. Pneumomol Alergol Pol, 2010, 78: 68 -73 .
10. Polosa R. Critical appraisal of antileukotriene use in asthma management. Curr Opin Pulm Med, 2007, 13: 24-30 .
11. Currie GP, McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann Allergy Asthma Immunol, 2006, 97: 731 -741.
12. Droszcz W. Antileukotrienes in asthma-critical view. Pneumomol Alergol Pol, 2010 , 78 : 60-67.
13. Guilpain P, Pagnoux C, Lhote F, et al. Antileukotrienes and Churg-Strauss syndrome. Preese Med, 2007, 36: 890-894 .
14. Wouden JC, Uijen JH, Bernsen RM, et al. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Sysr Rev,2008, 8: CD002173.
15. Guevara JP, Duchame FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma.Cochrane Database Sysr Rev, 2006, 19: CD003558.
16. Sridhar AV, McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev, 2006 , 19: CD004108.
17. Ortega VE, Peter SP. Beta-2 adrenergic agonists: focus on safety and benefits versus risks. Curr Opin Pharmacol, 2010, 6: 246 -253.
18. Michael J, Walters E, Walters J, et al. Adverse effects of betaagonists:are they clinically relevant? Am J Respir Med, 2003, 2 :287 -297.
19. Gupta P, Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people:recommendations for prescribing. Drugs Aging, 2008, 25: 415-443 .
20. 賴克方. 支氣管哮喘非特異性免疫治療. 實用醫(yī)院臨床雜志,2007, 4: 19-21.
21. Pipe A, Botturi K, Pinot D, et al. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy.Respir Med, 2009 , 103: 800-812.
22. Niederberger V. Allergen-specific immunotherapy. Immunol Lett,2009, 122: 131-133.
23. Passalacqua G, Durham SR; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol, 2007, 119: 881 -891.
  1. 1. Anandan C, Nurmatov U, Van Schayck OC, et al. Is the prevalence of asthma declining? Systematic review of epidemiological studies.Allergy, 2010 , 65: 152-67 .
  2. 2. Gibson PG, Powell H, Gibson PG. Initial corticosteroid therapy for asthma. Curr Opin Pulm Med, 2006, 12: 48-53 .
  3. 3. Kaiser H. Cortison therapy today. Wien Klin Wochenschr, 2003 ,115: 6 -21 .
  4. 4. Sasaki A, Ouchi K, Makata H, et al. The effect of inhaled corticosteroids on Chlamydophila pneumoniae and Mycoplasma pneumoniae infection in children with bronchial asthma. J Infect Chemother, 2009, 15: 99 -103.
  5. 5. Mullaoglu S, Turktas H, Kokturk N, et al. Esophageal candidiasis and Candida colonization in asthma patients on inhaled steroids.Allergy Asthma Proc, 2007, 28: 544-549 .
  6. 6. Sekine A, Hagiwara E, Ogura T, et al. A case of pulmonary Mycobacterium avium infection presenting multiple nodules with substantial difference in 18F-fluorodeoxyglucose uptake. Nihon Kokyuki Gakkai Zasshi, 2009, 47: 575-580 .
  7. 7. Christensson C, Thoren A, Lindberg B, et al. Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects. Drug Saf, 2008 , 31: 965-988.
  8. 8. Gluck PA, Gluck JC. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr Med Res Opin,2005, 21: 1075-1084 .
  9. 9. Fal AM, Kopec A. Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment. Pneumomol Alergol Pol, 2010, 78: 68 -73 .
  10. 10. Polosa R. Critical appraisal of antileukotriene use in asthma management. Curr Opin Pulm Med, 2007, 13: 24-30 .
  11. 11. Currie GP, McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann Allergy Asthma Immunol, 2006, 97: 731 -741.
  12. 12. Droszcz W. Antileukotrienes in asthma-critical view. Pneumomol Alergol Pol, 2010 , 78 : 60-67.
  13. 13. Guilpain P, Pagnoux C, Lhote F, et al. Antileukotrienes and Churg-Strauss syndrome. Preese Med, 2007, 36: 890-894 .
  14. 14. Wouden JC, Uijen JH, Bernsen RM, et al. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Sysr Rev,2008, 8: CD002173.
  15. 15. Guevara JP, Duchame FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma.Cochrane Database Sysr Rev, 2006, 19: CD003558.
  16. 16. Sridhar AV, McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev, 2006 , 19: CD004108.
  17. 17. Ortega VE, Peter SP. Beta-2 adrenergic agonists: focus on safety and benefits versus risks. Curr Opin Pharmacol, 2010, 6: 246 -253.
  18. 18. Michael J, Walters E, Walters J, et al. Adverse effects of betaagonists:are they clinically relevant? Am J Respir Med, 2003, 2 :287 -297.
  19. 19. Gupta P, Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people:recommendations for prescribing. Drugs Aging, 2008, 25: 415-443 .
  20. 20. 賴克方. 支氣管哮喘非特異性免疫治療. 實用醫(yī)院臨床雜志,2007, 4: 19-21.
  21. 21. Pipe A, Botturi K, Pinot D, et al. Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy.Respir Med, 2009 , 103: 800-812.
  22. 22. Niederberger V. Allergen-specific immunotherapy. Immunol Lett,2009, 122: 131-133.
  23. 23. Passalacqua G, Durham SR; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol, 2007, 119: 881 -891.